cyrilzakka/clinical-trials huggingface dataset:
The Effect of Remote Ischemic Preconditioning on Physical Performance and Exertional Rhabdomyolysis

In order to examine the effect of RIPC on skeleton muscle exertional damage and on aerobic and anaerobic physical performances, 30 healthy volunteers will undergo a series of different physical tests twice; once without intervention and a second time with RIPC intervention or placebo (false) intervention.

30 healthy civilians volunteers will be recruited and divided randomly into 2 groups: RIPC group and control group.

The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:

Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).

The first series will be performed without applying any intervention and is considered as baseline measurements for both groups. the second series will be performed as follows: a. RIPC group: applying RIPC exposure (placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats) at the beginning of every meeting. b. control group: with placebo (false) exposure (placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats) at the beginning of every meeting.

Blood ample, lactic acid and urine sample will be tested at the beginning and end of every meeting (testing for muscle, skeleton and kidney function markers).

Eligibility Criteria:
Inclusion Criteria:

* aged 18-30
* healthy civilians volunteers
* with no background illnesses
* above average fitness

Exclusion Criteria:

* known chronic medical illness
* routine medication usage
* history of rhabdomyolysis
* the physician decision
Changes in Body Composition With Patients Under Androgen Deprivation Therapy

This study aimed to evaluate the correlation of change in body composition and oncological outcomes of prostate cancer patients under androgen deprivation therapy(ADT).

Sarcopenia, decrease lean body mass (LBM) is the well-known parameter which negatively related to physical activity, morbidity and patients survival. Aging and decreased blood androgen level are well known risk factors of sarcopenia in male population.

Androgen deprivation therapy (ADT) is commonly performed in advanced or recurred prostate cancer patient and lead to accelerating decreasing blood androgen level. The previous studies defined the sarcopenia after ADT by calculated the (muscle component area) / (total body area) on computed tomography (CT) scan. However, CT scan is not recommended for routine follow up examination of ADT patients thus this measurement of sarcopenia has limitation on clinical usage.

This study using Inbody 320 for measure body composition. Inbody 320 based on multi-frequency Bioelectrical Impedance Analysis(BIA) method that calculated specific body component by differences in impedance indexes of fat, muscle and extracellular body fluid. Inbody measurement show precision accuracy and safety on body composition measurement, thus it frequently used in studies of obesity, nutrition and sports fields.

We calculating the total skeletal muscle mass (SMM), skeletal muscle index(SMI), relative skeletal muscle mass index (RASM), fat body mass (FBM), body mass index (BMI), body fat percentage, body water content, and edema value by Inbody 320 in the patients who treated by ADT in prostate cancer patients. Enrolled patients check the body composition parameters at the baseline (before ADT) and after ADT 3,6,12,18,24 months.

We prospectively measuring the 2 years changes of body composition and sarcopenia after ADT treatment. Patients characteristics (Age, underlying disease), Prostate cancer status (PSA level, Gleason grade group, initial treatment), ADT methods characters (timing, type) and oncological outcome (Recurrence, Metastasis, Castration resistance) were measuring in the cohort population.

Post hoc analysis were performed in the timing (initial, salvage or adjuvant) or type (LHRH agonist, Antiandrogen or surgical castration) of ADT for development of sarcopenia. Sub-arm analysis were performed for assessing that effect of presence of sarcopenia on oncological outcome and functional outcomes after ADT.

Eligibility Criteria:
Inclusion Criteria:

* Age over 20 year-old
* Patient with ECOG-PS 0 to 2
* Prostate cancer patients
* Considered Androgen deprivation therapy with any cause
* Patient agreed with informed consent of this study

Exclusion Criteria:

* History of previous ADT
* Planned intermittent treatment or short term ADT (less than 2 year)
* Contraindication of ADT
* Severe cognitive impairment, who cannot eligible for survey
* Secondary malignancy
* Patient cannot perform InBody test because of physical or underlying disease.
A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients

Early gastric cancer（AGC）has no effective characteristic symptoms and signs according to clinical statistics. Neoadjuvant chemotherapy (NAC) significantly reduces the size of AGC tumors so that it has become the recommended treatment for AGC in major guidelines. However, Some patients miss the best time for surgical treatment and may have irreversible chemotherapy side effects due to NAC lacks the guidance of new indicators for precise treatment such as molecular biomarkers. Tumor organoids are highly consistent with the clinical drug sensitivities of patients which could be used as clinical treatment prediction models thus providing guidance for individualized medicine. Therefore, the project is the first to carry out the prospective study by screening the potential benefit populations of NAC based on tumor organoids drug susceptibility experiment. The following hypothesis are put forward：the potential benefit population of NAC screened by tumor organoid drugs susceptibility technology will have better clinical efficacy, better treatment tolerance and higher adverse reaction rate.


Eligibility Criteria:
Inclusion Criteria:

1. Age: 18-75 years old;
2. Qualitative diagnosis: gastroscopic biopsy confirmed adenocarcinoma;
3. Localization diagnosis: the tumor is located in the stomach or gastroesophageal junction;
4. The clinical staging is stage III:

   A. Assess tumor stage: T3-4N1-2; B. Excluding distant organ metastasis (M0);
5. Physical condition (ECOG) score ≤ 1 point;
6. Those with effective preoperative neoadjuvant therapy and successful surgery agreed to receive 5 cycles of standard SOX chemotherapy after surgery;
7. Sign the informed consent form and be willing to participate in this project.

Exclusion Criteria:

1. Simultaneous or metachronous multiple primary malignant tumors;
2. Preoperative imaging examination results showed that there was distant metastasis;
3. Preoperative imaging findings:

   A. The tumor involving surrounding organs requires combined organ resection; B. Distant organ metastases; C. Those who cannot perform R0 resection;
4. Past history of malignant tumor;
5. Abnormal heart, lung, liver, kidney, hematopoietic function and bone marrow reserve function, unable to tolerate surgical treatment and chemotherapy;
6. Mental illness or other serious cardiovascular disease;
7. Pregnant or lactating women.
Pneumatic Compression and Post-induction Hypotension

The purpose of this study is to evaluate the effect of pneumatic compression on post-induction hypotension in elderly patients undergoing robot assisted laparoscopic prostatectomy.

The purpose of this study is to evaluate the effect of pneumatic compression of lower leg, which is performed during 20 minutes after anesthesia induction period, on post-induction hypotension in elderly patients undergoing robot assisted laparoscopic prostatectomy.

Eligibility Criteria:
Inclusion Criteria:

* Patients who are scheduled robot assisted laparoscopic prostatectomy under general anesthesia
* Elderly patients (between 65 and 79 years old)
* American Society of Anesthesiologists physical status ≤3
* Patients who are voluntarily agreed to this clinical study

Exclusion Criteria:

* Uncontrolled hypertension, heart failure (ejection fraction \<40%), arrhythmia requiring treatment, unstable coronary artery disease
* Patient's denial
The Effect of Methods Used in Oral Antipyretic Administration on the Vital Findings of the Child With Fever

Fever, one of the most common clinical journeys of childhood, makes up a fraction of emergency room admissions. About us-30. High fever, which is one of the first schools in infancy and childhood, can cause health problems such as not applying or starting the intervention. The most preferred method in the fire; antipyretic drug treatment in the hospital is routine . Antipyretics play a role in control plans and estimations of facts for cars of cars, the importance of word of mouth has some problems. In children, hospital, health care, injectors are grown from the breeder after completion, they can be created by red supplementation from the effects such as rearing without completion . resistance children; aspiration is risky, wrong dose is administered. It is stated in relation to teachers and verbal medicines for health. Hansen et al. Working with 61 babies aged 0-24 months, using a pacifier injector and a normal injector, children and temperature monitors. They are from the nipple injector used by mothers and women. There is a need for a new modification in the existing oral drug applications that will be able to support the adaptation and readiness of the child and to be able to effectively administer the drug. This work; Two different methods used to give antipyretic (medication pacifier and colored injector) were planned to be performed as pain, fever and purpose of life (respiratory rate, planning CTA) for the child.


Eligibility Criteria:
Inclusion Criteria:

* Applying to the pediatric emergency department with a complaint of high fever (38ºC).
* Being prescribed an antipyretic (paracetamol) by a physician.
* Those whose parents are literate and agree to participate in the study.
* Patients with triage color classification Yellow and Green.
* Children between 0-24 months will be included in the study.

Exclusion Criteria:

* Having used antipyretics in the last 6 hours.
* Being prescribed an antipyretic other than paracetamol by the physician.
* Having trouble in sucking-swallowing coordination.
* Children with chronic disease and neuromotor developmental delay.
Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial

To compare SBDECT with standard Triple Phase Multi-Detector CT (TPMDCT) in renal mass evaluation in terms of appropriateness of treatment received after diagnosis. To determine SBDECT diagnostic accuracy.


Eligibility Criteria:
Inclusion Criteria:

* Patients with suspected renal masses needing further evaluation with a contrast enhanced CT scan
* Patients who are referred for CT Urography

Exclusion Criteria:

* Patients not willing to participate in the study
* Age \<18 yrs
* Pregnant females
* Patients with previous h/o serious allergic reactions or Contrast allergy
* Impaired renal function (estimated GFR\<45mL/min/mm2)
* Sonographically proven benign renal mass needing no further evaluation
Hypospadias and Exome: Identification of New Genes for Familial Hypospadias

Hypospadias is the second most common malformation of the male genitalia and consists in a congenital hypoplasia of its ventral face. Hypospadias results from abnormal development of the penis that leaves the urethral meatus proximal to its normal glanular position. Meatus position may be located anywhere along the penile shaft, but more severe forms of hypospadias may have a urethral meatus located at the scrotum or perineum. Glandular and penile anterior represents approximately 70% of all the diagnosed cases.

The frequency of family reached depend on the severity of hypospadias. The number of children which have hypospadias mutation discovered by classical technique is low. Families are often the cause of the discovery of new genes involved in sexual differentiation because they allow comparison of genomes of related persons, and detect more easily mutations.

The aim of this protocol is to search for new genes involved in genital malformations such as hypospadias. Addressed to families with usual causes of these malformations excluded. The search for these mutations will be done by exome sequencing in families where several cases of hypospadias were identified.

Eligibility Criteria:
Inclusion Criteria:

* Hypospadiac patients with a familial history of hypospadias

Exclusion Criteria:

* Hypospadiac patients without a family history of hypospadias
* Hypospadiac patients with a family history of hypospadias where etiology is identified
Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage

The purpose of this study is to determine whether prostacyclin is effective in prevention of cerebral vasospasm in patients with subarachnoidal hemorrhage (SAH).


Eligibility Criteria:
Inclusion Criteria:

* SAH verified by CT
* Aneurysm identified and treated
* Fisher grade 3 + 4
* WFNS grade 1-4 (World Federation of Neurosurgical Societies )

Exclusion Criteria:

* Pregnancy/lactation
* Heard failure
* Kidney failure
* Liver failure
* Hemorrhagic diathesis
Intra Oral Scan and CBCT Aided Diagnosis of Dental Plaque and Caries

In this prospective controlled trial, patients will be enrolled at the University Hospital Ghent. Inclusion criteria are: age between 18 and 70 years old, presence of 20 or more teeth, and have a minimum one carious tooth surface. All participants have to sign an informed consent. Pregnant women will be excluded. First an intra-oral scan will be taken for visual plaque detection. Thereafter, plaque scores will be noted after visual inspection and with plaque staining. After supra-gingival calculus removal and oral hygiene instructions bite-wing radiographs will be taken and a visual caries inspection will be performed. Finally, a new intra-oral scan will be taken for visual caries detection, followed by a CBCT scan.

Minimally 2 weeks after this intervention, plaque-scores and caries-scores will be measured by an independent researcher and the same researcher on the intra-oral scans, CBCT and radiographs(Pictures taken with X-rays to view the inside of your teeth and jawbone)(for caries detection).

The following variables will be measured:

1. Plaque measurement: 1) Plaque detection using intra-oral scan images (white light (and fluorescence)) will be performed and compared with 2) the assessment of visual plaque detection and 3) using plaque staining (golden standard). The findings will be recorded in a plaque status through the website www.parodontalstatus. And exported to be attached to the anonymized patient file.
2. Caries: The results of caries detection by intra-oral scan and bite-wing radiographs will be compared with the results of clinical caries detection and bite-wing radiographs on one hand and the CBCT images on the other hand. ICDAS scores will be registered for the visual assessment, CBCT and bite-wing radiograph images assessment.

The following step-by-step protocol will be used:

The digital data, including images, that will be the subject of the research will be acquired using 3SHAPE's Trios 5 intra-oral scan. The CBCT image will be made with the ProMax 3D of Planmeca. These two imaging techniques will be the only study specific handeling during the study.

1. explanation to patients
2. take an intra-oral scan (STUDY SPECIFIC)
3. conventional visual inspection and palpation plaque scoring
4. plaque staining (record with parostatus.ch)
5. take an intra-oral scan with plaque staining in a situation that is viewed on site, in the mouth, without removing or moving anything.(STUDY SPECIFIC)
6. calculus removal and cleaning
7. take bite-wing radiographs
8. visual caries detection
9. take a thirth intra-oral scan (STUDY SPECIFIC)
10. CBCT scan (STUDY SPECIFIC)
11. plaque detection on IOS images and caries detection using IOS images and CBCT images


Eligibility Criteria:
Inclusion Criteria:age between 18 and 70 years old, presence of 20 or more teeth, and have a minimum one carious tooth surface -

Exclusion Criteria:Pregnant women will be excluded -
Effectiveness of a Diuretic Algorithm in Clinical Stability in Heart Failure Patients

One of the challenges in treating patients with heart failure (HF) is achieving clinical stability and reducing the hospital readmission rate. A diuretic dose adjustment algorithm developed in the United States (Diuretic Treatment Algorithm, DTA) and later validated for use in Brazil (as the Algoritmo de Ajuste de Diurético, AAD) has proved feasible and readily applicable, but its effect on clinical outcomes has yet to be assessed. This report aims to describe a randomized clinical trial protocol designed to assess the effectiveness of the AAD and of nonpharmacologic management in improving clinical stability and reducing the readmission rate at 90 days in patients with HF.

A PROBE (prospective randomized open blinded endpoint) parallel-group design will be used. Adult patients with a diagnosis of reduced ejection fraction HF, who are being treated at a specialized HF clinic are being recruited. Those with indications for loop diuretic dose adjustment during routine clinic visits will be randomized to take part in the trial. Participants in the intervention group (IG) shall have their diuretic doses adjusted in accordance with the AAD and receive four telephone calls (one per week) over 30 days to reinforce guidance on nonpharmacological management (fluid and sodium restriction). Participants in the control group (CG) shall have their diuretic doses adjusted by a physician during the first trial visit and shall not receive any telephone calls. Patients in both groups shall return at 1 month for face-to-face reassessment. The study endpoints shall comprise readmission and/or emergency department visits due to HF decompensation within 90 days and clinical instability. All participants shall be required to have a scale at home (or easy access to one), a telephone number, agree to telephone-based follow-up, and be available to return for a 1-month trial visit. Overall, 135 patients are expected to be enrolled in each group.

Eligibility Criteria:
Inclusion Criteria:

* Patients of both genders
* Age ≥ 18 years
* Diagnosed with systolic HF
* Able to monitor body weight at home
* Using furosemide

Exclusion Criteria:

* Those who are not able to make return visits or participate in telephone contact, and those on renal replacement therapy.
First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

The purposes of this study are to determine:

The safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or docetaxel with carboplatin and any side effects that might be associated with the combination of these drugs.

Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can help participants with non-small cell lung cancer (NSCLC) live longer, compared with the combination of docetaxel and carboplatin.

Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can make your tumor smaller or disappear, and for how long, compared with the combination of docetaxel and carboplatin.

The effects of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin or docetaxel with carboplatin have on your disease related symptoms.

The relation of smoking history and hormone replacement therapy (for women only) may have to your lung cancer treatment results.

The effects of certain genes and proteins in samples of your blood and tumor tissue in order to learn more about NSCLC and how enzastaurin works in the body.


Eligibility Criteria:
Inclusion Criteria:

* You must have been diagnosed with NSCLC.
* You must be able to visit the doctor's office weekly during the active treatment period and as needed during the study follow-up period.
* You must be willing and able to swallow capsules.
* Your entry labs and medical tests must meet study requirements.
* You must be willing to have blood samples drawn and tissue samples obtained for gene and protein testing.

Exclusion Criteria:

* You have received radiation within 2 weeks of study enrollment.
* You have previously received any anti-cancer drug therapy for NSCLC.
* You have an active infection or other serious condition.
* You take aspirin or aspirin-like medication regularly and are not able to stop taking them for a few days during each cycle of chemotherapy.
* You have recently lost a significant amount of weight.
A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America

The main objectives of this observational cohort study are to describe the use of intravitreal aflibercept and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Latin America for a study population of treatment naive patients and those who have received prior therapy (anti-VEGF injections, laser, steroids, etc.) and are being switched to intravitreal aflibercept injection.


Eligibility Criteria:
Inclusion Criteria:

* Age: ≥18 years of age for DME patients,
* Age: ≥55 for wAMD patients
* Decision to treat with intravitreal aflibercept in the study eye prior to patient enrolment as per the physician's routine clinical practice and following the local Product monograph recommendations. Patients who are treatment naïve (no previous intravitreal treatment received, including, anti- VEGF agents, steroids, steroid implants and/or PDT) and patients that are switching from a different anti-VEGF therapy are both eligible to be included. DME patients that have received previous laser only will be classified as treatment naïve.
* If of childbearing potential, female willing to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of aflibercept

Exclusion Criteria:

* Patients participating in an investigational program with interventions outside of routine clinical practice.
* Patients currently being treated with intravitreal aflibercept in the study eye.
* Patients who are hypersensitive to this drug, to any ingredient in the formulation, or to any component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the local product monograph.
* Ocular or peri-ocular infection in either eye.
* Active intraocular inflammation in the study eye.
* Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
* Patients with advanced glaucoma, visually significant cataracts, or any eye disease likely to require surgery during the study period in the study eye.
* Concomitant ocular or systemic administration of drugs that could interfere with or potentiate the mechanism of action of intravitreal aflibercept, including anti-VEGF agents.
* Patients receiving a different anti-VEGF agent other than intravitreal aflibercept for the fellow eye.